The effect of rifampin on the pharmacokinetics of famitinib in healthy subjects.
Background: Famitinib is an oral, small-molecule, multi-targeted tyrosine kinase inhibitor under clinical investigation for the treatment of solid tumors. As famitinib is metabolized mainly by cytochrome P450 3A4 (CYP3A4), the study was conducted to investigate the effect of potent CYP3A4 inducer ri...
| Publicado en: | Cancer Chemotherapy & Pharmacology Vol. 90; no. 5; pp. 409 - 416 |
|---|---|
| Autores principales: | , , , , , , , , , , , |
| Formato: | Journal Article |
| Publicado: |
Springer Nature
Nov2022
|
| Acceso en línea: | Ver este registro en EBSCOhost |